Literature DB >> 22134049

Cordycepin inhibits renal interstitial myofibroblast activation probably by inducing hepatocyte growth factor expression.

Li Li1, Dongyuan He, Junwei Yang, Xiaoyun Wang.   

Abstract

Renal interstitial fibrosis is the common end point of progressive renal diseases leading to the deterioration and eventual loss of renal function. This study investigated the effect and potential mechanism of cordycepin on activation of renal interstitial fibroblast cells. The time and dose-responses of cordycepin in rat renal interstitial fibroblast (NRK-49F) cells were analyzed. The proliferation of NRK-49F and the expression of α-smooth muscle actin (α-SMA) and fibronectin (FN) were examined. The expression and translocation of Smad proteins also were measured by western blot and indirect immunofluorescence staining. The mRNA level of hepatocyte growth factor (HGF) and the expression of HGF receptor c-Met and its phosphorylation (p-Met) were also detected. Cordycepin suppressed the proliferation of NRK-49F and the expression of α-SMA and FN induced by transforming growth factor-β1 (TGF-β1). The pretreatment of cordycepin markedly attenuated the nuclear translocation and accumulation of activated Smad2/3 in NRK-49F cells. Furthermore, cordycepin not only increased HGF expression, but also induced HGF secretion, as well as HGF receptor phosphorylation in NRK-49F cells. Cordycepin possesses renoprotective activity through suppression myofibroblast activation. This action is mediated, at least in part, by blocking nuclear translocation and accumulation of activated Smad2/3 protein and up-regulating anti-fibrotic HGF expression and secretion and HGF receptor activation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22134049     DOI: 10.1254/jphs.11127fp

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  7 in total

1.  The protective effect of Cordycepin on diabetic nephropathy through autophagy induction in vivo and in vitro.

Authors:  Tao Cao; Ricong Xu; Yi Xu; Yang Liu; Dongli Qi; Qijun Wan
Journal:  Int Urol Nephrol       Date:  2019-07-29       Impact factor: 2.370

Review 2.  Mechanism of Cordyceps sinensis and its Extracts in the Treatment of Diabetic Kidney Disease: A Review.

Authors:  Wu Liu; Yiwei Gao; Yi Zhou; Fangning Yu; Xinyi Li; Ning Zhang
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

3.  Cordycepin prevented IL-β-induced expression of inflammatory mediators in human osteoarthritis chondrocytes.

Authors:  Xiaozhou Ying; Lei Peng; Hua Chen; Yue Shen; Kehe Yu; Shaowen Cheng
Journal:  Int Orthop       Date:  2013-12-12       Impact factor: 3.075

4.  Cordycepin, a Characteristic Bioactive Constituent in Cordyceps militaris, Ameliorates Hyperuricemia through URAT1 in Hyperuricemic Mice.

Authors:  Tianqiao Yong; Shaodan Chen; Yizhen Xie; Diling Chen; Jiyan Su; Ou Shuai; Chunwei Jiao; Dan Zuo
Journal:  Front Microbiol       Date:  2018-01-25       Impact factor: 5.640

Review 5.  A Systematic Review of the Biological Effects of Cordycepin.

Authors:  Masar Radhi; Sadaf Ashraf; Steven Lawrence; Asta Arendt Tranholm; Peter Arthur David Wellham; Abdul Hafeez; Ammar Sabah Khamis; Robert Thomas; Daniel McWilliams; Cornelia Huiberdina de Moor
Journal:  Molecules       Date:  2021-09-28       Impact factor: 4.411

6.  Hirsutella sinensis mycelium suppresses interleukin-1β and interleukin-18 secretion by inhibiting both canonical and non-canonical inflammasomes.

Authors:  Tsung-Teng Huang; Kowit-Yu Chong; David M Ojcius; Yi-Hui Wu; Yun-Fei Ko; Cheng-Yeu Wu; Jan Martel; Chia-Chen Lu; Hsin-Chih Lai; John D Young
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

7.  Renal Injury during Long-Term Crizotinib Therapy.

Authors:  Taro Yasuma; Tetsu Kobayashi; Corina N D'Alessandro-Gabazza; Hajime Fujimoto; Kentaro Ito; Yoichi Nishii; Kota Nishihama; Prince Baffour Tonto; Atsuro Takeshita; Masaaki Toda; Esteban C Gabazza; Osamu Taguchi; Shigenori Yonemura; Osamu Hataji
Journal:  Int J Mol Sci       Date:  2018-09-25       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.